A predictive classifier of poor prognosis in transplanted patients with juvenile myelomonocytic leukemia: a study on behalf of the Soci&#233;t&#233; Francophone de Greffe de Moelle et de Th&#233;rapie Cellulaire

Meyran, D; Arfeuille, C; Chevret, S; Neven, Q; Caye-Eude, A; Lainey, E; Petit, A; Rialland, F; Michel, G; Plantaz, D; Jubert, C; Theron, A; Gandemer, V; Ouach&#233;e-Chardin, M; Paillard, C; Bruno, B; Buchbinder, N; Pochon, C; Calvo, C; Fahd, M; Baruchel, A; Cav&#233;, H; Dalle, JH; Strullu, M

A predictive classifier of poor prognosis in transplanted patients with juvenile myelomonocytic leukemia: a study on behalf of the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire

Author(s): Meyran, D; Arfeuille, C; Chevret, S; Neven, Q; Caye-Eude, A; Lainey, E; Petit, A; Rialland, F; Michel, G; Plantaz, D; Jubert, C; Theron, A; Gandemer, V; Ouachée-Chardin, M; Paillard, C; Bruno, B; Buchbinder, N; Pochon, C; Calvo, C; Fahd, M; Baruchel, A; Cavé, H; Dalle, JH; Strullu, M;
Details: Publication Year 2024-09-01,Volume 109,Issue #9,Page 2908-2919
Journal Title: Haematologica
Publication Type: Research article
Abstract: Juvenile myelomonocytic leukemia (JMML) is an aggressive pediatric myeloproliferative neoplasm requiring hematopoietic stem cell transplantation (HSCT) in most cases. We retrospectively analyzed 119 JMML patients who underwent first allogeneic HSCT between 2002 and 2021. The majority (97%) carried a RAS-pathway mutation, and 62% exhibited karyotypic alterations or additional mutations in SETBP1, ASXL1, JAK3 and/or the RAS pathway. Relapse was the primary cause of death, with a 5-year cumulative incidence of 24.6% (95% CI: 17.1-32.9). Toxic deaths occurred in 12 patients, resulting in treatment-related mortality (TRM) of 9.0% (95% CI: 4.6-15.3). The 5-year overall (OS) and event-free survival were 73.6% (95% CI: 65.7-82.4) and 66.4% (95% CI: 58.2-75.8), respectively. Four independent adverse prognostic factors for OS were identified: age at diagnosis >2 years, time from diagnosis to HSCT ≥6 months, monocyte count at diagnosis >7.2x109/L, and the presence of additional genetic alterations. Based on these factors, we proposed a predictive classifier. Patients with 3 or more predictors (21% of the cohort) had a 5-year OS of 34.2%, whereas those with none (7%) had a 5-year OS of 100%. Our study demonstrates improved transplant outcomes compared to prior published data, which can be attributed to the synergistic impacts of a low TRM and a reduced, yet still substantial, relapse incidence. By integrating genetic information with clinical and hematologic features, we have devised a predictive classifier. This classifier effectively identifies a subgroup of patients who are at a heightened risk of unfavorable post-transplant outcomes who would benefit from novel therapeutic agents and post-transplant strategies.
Publisher: Ferrata-Storti Foundation
Keywords: Humans; *Leukemia, Myelomonocytic, Juvenile/genetics/therapy/mortality/diagnosis; Male; Female; *Hematopoietic Stem Cell Transplantation; Child, Preschool; Prognosis; Infant; Child; Retrospective Studies; Mutation; Adolescent
Department(s): Laboratory Research
Publisher's Version: https://doi.org/10.3324/haematol.2023.284103
Open Access at Publisher's Site: https://doi.org/10.3324/haematol.2023.284103
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2024-09-19 02:59:42

Last Modified: 2024-09-19 03:00:01